3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Other solid neoplasm
2
Conditions
Pancreatic Neoplasms
3
Ovarian Neoplasms
2
Mesothelioma, Malignant
2
Mesothelioma
2
Carcinoma, Non-Small-Cell Lung
2
Severe combined immunodeficiency with sensitivity to ionizing radiation
1
Neoplasms
1
Interventions
Pemetrexed
13
Cisplatin
12
Nivolumab
5
Carboplatin
5
pembrolizumab
4
Ipilimumab
4
Cyclophosphamide
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
fludarabine
3
defactinib
3
amatuximab
2
Paclitaxel
2
Gemcitabine
2
Drug Therapy
2
tremelimumab
1
tazemetostat
1
osimertinib
1
napabucasin
1
enzalutamide
1
bemcentinib
1
abemaciclib
1
VS-5584
1
Trabectedin
1
Thiostrepton
1
Safety
1
Panobinostat
1
Monatide (IMS 3015)
1
Midazolam
1
Letrozole
1
LY3023414
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Mesothelioma, Malignant
×
amatuximab
×
Clear all
NCT00738582
2022-09-22
Amatuximab
Morphotek
Phase 2
Completed
89 enrolled
12 charts
NCT02357147
2020-03-17
ARTEMIS
Morphotek
Phase 2
Terminated
124 enrolled
10 charts